Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) — A Broken Guide, Not Yet a Broken Franchise

Report date: 2026-08-22 Update baseline: 2026-06-21 Last market close used: $236.22 on 2026-08-21 Research framing: Fundamental, competitive-advantage-driven, evidence-based. Recommendation and price zones appear only in the deliberately labeled Claude’s Take; the institutional body contains scenario analysis but no recommendation or price target.

Claude’s Take

This is the analyst assistant’s subjective opinion, separated from the evidence-led institutional body. It is not investment advice.

Verdict: ACCUMULATE-ON-WEAKNESS / BUY THE RESET, medium conviction. At $236, Alnylam is no longer priced for a flawless AMVUTTRA cardiomyopathy launch. That matters because the launch was not flawless: management cut the FY2026 TTR range by $200M at the midpoint after discovering that early second-line demand contained more pent-up switching than it understood. The admission was important and the prior ramp assumption is falsified. But the evidence does not establish that AMVUTTRA is losing the franchise: Q2 TTR revenue still grew 89% year over year and 13% sequentially, demand reaccelerated, adherence remains above 90%, the prescriber base is broadening, and a direct silencer competitor just failed its pivotal cardiomyopathy endpoint. The market erased roughly half the equity value from the October 2025 peak while the company became profitable and self-funding.

I would build a position in a $210–260 entry zone, becoming more aggressive near or below $210 only if the next quarter confirms demand and first-line prescriber expansion. My directional value zone is $300–390, with a downside zone around $160–190 if AMVUTTRA first-line share and margins both deteriorate, and a bull outcome above $450 if the TTR franchise approaches management’s 2030 ambition while nucresiran and at least one beyond-TTR program de-risk. Those zones are scenario markers, not point estimates.

The case is not “the guide cut does not matter.” It matters enough to lower confidence and demand a wider margin of safety. The case is that a one-time commercial forecasting error has been capitalized as though it proves permanent moat erosion. That is not yet supported. The strongest moat is Alnylam’s accumulated RNAi chemistry, delivery, clinical-data, manufacturing and regulatory know-how; the weakest is customer captivity in an expanding cardiology market where Attruby is taking starts and physicians can choose an oral stabilizer. The stock is therefore a de-rated platform leader with an execution scar, not a low-risk compounder.

What changed since 2026-06-21. The prior view was HOLD/accumulate weakness around $278. Since then the TTR guide was cut, which partially triggers the pre-registered bull kill test; eplontersen failed CARDIO-TTRansform, which weakens a key competitive bear claim but adds combination-trial scrutiny; Congress broadened the IRA orphan exclusion, making the prior automatic-exclusion concern stale under current law; and the stock fell another 15% despite a strongly favorable biotech tape. The lower price improves prospective asymmetry, but the forecasting miss reduces confidence. The result is a more constructive verdict at a lower price with no upgrade in conviction.

Tag: “The launch stumbled; the platform did not.”

Stock Price Action — Five-Year Event Map

ALNY closed at $236.22 on August 21, 2026, down about 15.1% from the June 18 baseline and 51.9% below its $491.22 October 2025 all-time high. It remains below the 21-, 50- and 200-day exponential moving averages of approximately $238, $260 and $310. The price path is now dominated by company-specific expectation resets: since June 18, IBB gained roughly 23% while ALNY fell, and the factor model attributes only 22% of return variance to common factors. Price data are facts from the AZI daily series; causal attributions are interpretations tied to dated disclosures.

The sequence matters. The July 9 reversal says the competitive win was not clean; the July 30 collapse says forecasting credibility and launch durability now dominate. Because biotech and relevant peers rose over the same interval, describing the decline as sector beta would be wrong. ALNY’s one-year Sharpe ratio of about -1.11, specific volatility near 43%, and weak negative Momentum loading reinforce the same point: this is an idiosyncratic reset.

1. Executive Summary

Alnylam is the leading commercial RNA-interference company. It owns four commercial products—AMVUTTRA and ONPATTRO in transthyretin amyloidosis, GIVLAARI in acute hepatic porphyria and OXLUMO in primary hyperoxaluria type 1—and earns collaboration and royalty economics from additional Alnylam-invented medicines. Q2 2026 product revenue reached $1.172B, including $1.012B of AMVUTTRA; total revenue was $1.291B. The TTR franchise contributed $1.030B, or 88% of product revenue. That concentration is both the source of current operating leverage and the central risk.

The quarter delivered conflicting evidence. TTR revenue increased 89% year over year and 13% sequentially, Q2 GAAP operating margin reached 17.9%, and H1 free cash flow was about $341M. Yet management reduced FY2026 TTR guidance from $4.4–4.7B to $4.2–4.5B and total product guidance from $4.9–5.3B to $4.7–5.1B. Management said the 2025 second-line launch cohort contained more pent-up patients progressing on stabilizers than it had understood and stated plainly that it “didn’t get it right.” This is a forecasting failure and a weaker growth mix, not merely timing.

The prior bull test required the original TTR ramp, stable or rising first-line share, operating leverage and eventual beyond-TTR validation. The guidance component is falsified. The compound thesis-break criterion is only partially triggered because Alnylam has not disclosed sequential first-line share loss, demand reaccelerated in Q2, and management says about 80% of category initiations now come from first-line patients. That last claim is category mix rather than auditable AMVUTTRA share, so independent prescription or payer-claims evidence remains necessary. BridgeBio’s Attruby grew U.S. revenue approximately 23% sequentially to $222.4M, confirming prescriptions are contestable.

Competitive supply improved near term when Ionis/AstraZeneca’s eplontersen missed the CARDIO-TTRansform primary endpoint. But the trial enrolled a contemporary population in which most patients used a stabilizer, and a nominal signal appeared in the monotherapy subgroup. The result reduces the probability of a near-term branded silencer competitor while increasing scrutiny of incremental benefit on background therapy. It is a positive commercial event for AMVUTTRA and a cautionary event for TRITON-CM at the same time.

The Greenwald assessment is therefore two-layered. Alnylam has a strong supply-side platform advantage: patents, tacit chemistry and delivery knowledge, manufacturing and process experience, a broad human safety database, regulatory repetition and economies of scope across targets. It has more moderate TTR-specific scale and physician-workflow advantages. It does not have strong customer captivity among treatment-naive cardiomyopathy patients. Oral stabilizers, future gene editing and amyloid-clearance antibodies compete across mechanism, convenience, evidence and price.

Capital-cycle analysis is similarly mixed. ATTR is a large, underdiagnosed and expanding profit pool, but high returns are attracting supply. Eplontersen’s failure removes one candidate; it does not change the late-decade queue of Attruby, tafamidis genericization, nexiguran ziclumeran editing, antibodies and Alnylam’s own nucresiran. The correct question is not whether the category grows. It is whether Alnylam captures enough of that growth, at attractive incremental economics, before the price umbrella and exclusivity narrow.

Financial quality has improved decisively. Q2 operating income was $231M and H1 operating cash flow $397M. Cash plus marketable securities totaled $3.308B against roughly $1.267B of convertible debt and leases. However, AMVUTTRA’s escalating Sanofi royalty compresses product gross margin as sales rise, and $1.720B of royalty/development funding liabilities belongs in an economic enterprise-value view. H1 stock compensation was $156.8M, down to 6.4% of revenue from 12.3% a year earlier. A correction to the prior report is essential: GAAP net income already includes SBC, so subtracting SBC again from net income double counts it. The appropriate owner-cash measure is FCF less the non-cash SBC add-back; H1 owner FCF on that basis was approximately $184M.

At $236.22, basic market capitalization is about $31.6B. Broad-cash enterprise value is about $29.5B; including royalty and development funding liabilities produces an economic EV near $31.3B. The broad-cash EV is roughly 6.2x trailing revenue, 29.6x trailing operating income and 5.2–5.6x implied FY2026 total revenue. These are not obviously distressed multiples, particularly against a low current owner-FCF yield. They are materially less demanding than the peak and place the burden of proof on durable TTR growth and margin conversion rather than on multiple expansion.

The central conclusion is narrow: a real guide reset does not yet equal a broken franchise. Evidence that would change that conclusion includes two consecutive quarters of first-line share loss, weak net-new prescriber productivity, renewed guide cuts, or persistent margin deterioration beyond the known Sanofi royalty effect. Evidence that would strengthen it includes auditable first-line share stabilization, sustained quarterly TTR demand growth, lower SBC as a share of revenue, and a decisive clinical-outcomes readout beyond TTR.

2. Business Quality, Industry Structure, and Competitive Position

Evidence scope and update framing

INTERPRETATION — The main change is not a binary collapse or confirmation of the prior thesis. Q2 simultaneously weakened confidence in the pace of AMVUTTRA’s commercial ramp, strengthened the near-term competitive runway after eplontersen failed in cardiomyopathy, and materially reduced the prior memo’s Medicare-negotiation concern after Congress broadened the orphan-drug exclusion. The evidence now supports a sharper distinction: Alnylam has a durable technical-platform advantage, but a narrower and actively contested product-market moat.

What changed since 2026-06-21

Business model and current economic engine

FACT — Alnylam commercializes four wholly owned products: AMVUTTRA and legacy ONPATTRO in ATTR amyloidosis, GIVLAARI in acute hepatic porphyria, and OXLUMO in primary hyperoxaluria type 1. It also receives collaboration revenue and royalties from partner products and programs, notably Novartis’s Leqvio and partner-distributed Alnylam-invented assets. For Q2 2026, product revenue was $1.172B, collaboration revenue $47.2M, royalty revenue $71.7M, and total revenue $1.291B. AMVUTTRA alone represented about 86% of product revenue; the combined TTR franchise represented about 88%. Alnylam Q2 release, 2026-07-30

INTERPRETATION — The business has two layers. The first is a concentrated, vertically integrated TTR profit engine in which Alnylam discovers, develops, and commercializes the drug. The second is a broader platform with lower-risk partner economics through milestones and royalties. The second layer validates the platform and diversifies scientific exposure, but it does not yet diversify the P&L enough to offset an AMVUTTRA-specific commercial disappointment.

FACT — Q2 GAAP operating income was $231.4M versus a $16.2M loss a year earlier, and cash plus marketable investments ended the quarter near $3.3B. Product gross margin was approximately 74.6%; cost of goods sold increased to 25.4% of product revenue from 21.1%, primarily because growing AMVUTTRA sales raise the blended royalty paid to Sanofi. GAAP R&D grew 28% to $413.1M and SG&A grew 8% to $347.9M as Alnylam funded ZENITH, TRITON-CM/TRITON-PN, and the AMVUTTRA launch. Alnylam Q2 release, 2026-07-30

INTERPRETATION — The platform has crossed into profitable self-funding, which is strategically important: it can fund trials, diagnosis efforts, global access, and next-generation chemistry without repeated equity issuance. The economic moat is weaker than a headline gross margin implies, however, because AMVUTTRA royalties are a variable burden and rising clinical/commercial investment absorbs much of the expanding gross profit.

RNAi platform moat — Greenwald assessment

Supply-side advantage: strong, but not exclusive

FACT — Alnylam’s GalNAc conjugates enable subcutaneous delivery of RNAi therapeutics to hepatocytes. The company’s ESC chemistry increased potency and duration to monthly, quarterly, or twice-yearly dosing; ESC+ was designed to expand therapeutic index, and the IKARIA design and nucresiran target twice-yearly or annual dosing. The company has translated the platform into multiple approved Alnylam-invented medicines, including partnered products, rather than a single molecule. Alnylam 2025 Form 10-K, filed 2026-02-12

INTERPRETATION — In Greenwald terms, the strongest barrier is a supply advantage built from interlocking patents, tacit chemistry and delivery know-how, manufacturing/process expertise, human safety data, and regulatory experience. The recurring output across targets is better evidence than patent count alone. Economies of scope also matter: one discovery platform, safety database, regulatory organization, and commercial-access infrastructure can be reused across programs.

FACT — The advantage is permeable. Alnylam’s current 10-Q lists RNAi competitors including Arrowhead, Amgen, AstraZeneca, Lilly, GSK, Novartis, Novo Nordisk, Silence, and Wave, and notes that several third parties have licenses or access to Alnylam intellectual property. Ionis’s GalNAc-enabled antisense products likewise use technology licensed from Alnylam. Alnylam Q2 2026 Form 10-Q, filed 2026-07-30

INTERPRETATION — Licensing is both evidence of valuable IP and evidence that Alnylam does not have exclusive control of all clinically useful gene-silencing delivery. The moat lowers technical risk and development cost relative to a new entrant; it does not eliminate molecule-specific efficacy, safety, trial-design, or commercial risk. CARDIO-TTRansform’s failure is a timely reminder that target knockdown is not the same thing as demonstrated clinical benefit in a contemporary treated population.

Customer captivity: moderate at the product level, weak as a category barrier

FACT — AMVUTTRA is a healthcare-professional-administered 25 mg subcutaneous injection every three months and is approved for both hATTR polyneuropathy and wild-type or hereditary ATTR cardiomyopathy. FDA AMVUTTRA label, revised 2025-03 Management reported adherence above 90%, more than 1,700 new prescribers since the CM launch, and approximately 80% of current category new-treatment initiations coming from first-line patients. It also said prescribers who have used AMVUTTRA employ it in more than half of their subsequent new starts, while only about one-third of the growing TTR prescriber pool has used it. Alnylam Q2 earnings call transcript, 2026-07-30

INTERPRETATION — Physician familiarity, office workflow, prior authorization, quarterly administration, and high persistence create real agency and switching frictions. Yet the stable-share test is not satisfied: the CM market is new, share is moving, and Attruby is growing rapidly. This is not a network-effect business. Customer captivity can help retain an established patient, but it is much weaker in treatment-naive starts where oral stabilizers, injectables, and future editors compete on outcomes, convenience, channel economics, and price.

OPEN QUESTION — Alnylam does not provide a directly auditable quarterly first-line share series. Management says share is strong and gradually progressing while BridgeBio says Attruby’s first-line share is rising. Both can be true in an expanding market, but neither statement alone resolves relative share. Prescription audits or payer claims are required to score this barrier independently.

Scale: meaningful within TTR, less decisive across the modality

FACT — Alnylam has a large specialist prescriber footprint, global commercialization, a >$1B quarterly TTR franchise, and growing cash generation. It is also funding the DemonsTTRate observational program for more than 2,000 patients with follow-up up to five years, which can expand real-world evidence and disease understanding. Alnylam Q2 release, 2026-07-30

INTERPRETATION — Scale is most defensible when paired with familiarity and an existing customer base: Alnylam can spend more per indication on diagnosis, evidence generation, market access, and global launch than a small entrant. Greenwald’s warning applies, however: a rapidly growing market makes fixed-cost scale easier for competitors to amortize. Pfizer, AstraZeneca, Novo, Regeneron, and BridgeBio either already have scale or can obtain it. Scale reinforces Alnylam’s lead; it does not close the market.

IP duration and replacement cadence

FACT — Selected U.S. AMVUTTRA patents extend from 2028 into 2035–2036, including method/composition claims; U.S. orphan exclusivity runs to June 2029 for PN and March 2032 for CM. The FDA orphan database confirms the two approval/exclusivity periods. Alnylam 2025 10-K, filed 2026-02-12; FDA orphan designation record, accessed 2026-08-22

INTERPRETATION — Patents and exclusivities are valuable but wasting assets. Nucresiran’s twice-yearly/annual potential and TRITON-CM/TRITON-PN program are therefore not simply pipeline upside; they are an internal replacement and exclusivity-refresh strategy. A genuine platform moat requires Alnylam to replace its own franchise before generic or modality competition does.

ATTR industry structure and competitor map

FACT — ATTR-CM is now an oligopolistic market with three approved mechanistic choices: Pfizer’s tafamidis products and BridgeBio’s Attruby stabilize the TTR tetramer, while AMVUTTRA silences hepatic TTR production. Alnylam’s 10-Q explicitly notes that the oral dosing and lower list prices of approved stabilizers can affect AMVUTTRA share and revenue. Alnylam Q2 2026 10-Q, filed 2026-07-30

INTERPRETATION — The relevant market is not “RNAi” but ATTR disease modification across modalities. Competition is governed by outcomes and label, line of therapy, dosing preference, access channel, physician comfort, and net price. A technically superior silencer platform can still lose a start to a convenient oral stabilizer.

INTERPRETATION — Value chain and profit pool. Upstream chemistry, delivery, and IP capture economic rent because they determine whether a target is druggable and durable. In ATTR, however, a second profit pool sits in diagnosis, specialist access, evidence generation, reimbursement, and patient persistence. Drug manufacturing itself is not the dominant barrier, though qualified oligonucleotide capacity matters. Physicians and payers are powerful agents because patients rarely choose directly; the payer can prefer an oral Part D drug, resist combination therapy, or demand a clinically meaningful incremental benefit for an office-administered product.

Reimbursement, IRA, FDA, and supply

FACT — AMVUTTRA is administered by a healthcare professional and has HCPCS code J0225. Medicare Part B generally reimburses most separately payable physician-administered drugs using average sales price plus a statutory add-on, while exact net economics vary by setting and payer. CMS ASP overview, accessed 2026-08-22; CMS ASP pricing files, accessed 2026-08-22

INTERPRETATION — Quarterly office administration supports persistence and makes silent nonadherence less likely, but it creates buy-and-bill, site-of-care, and prior-authorization friction that oral stabilizers do not share. The channel is thus both a retention mechanism and a competitive disadvantage. Management said it was not seeing meaningful reimbursement pushback and that some Medicare Advantage policies already restrict combinations; this is a management observation, not independent payer evidence. Alnylam Q2 call transcript, 2026-07-30

FACT — The revised Medicare negotiation statute now permits the orphan exclusion for one or more rare-disease designations when all approved indications are rare diseases. AMVUTTRA’s approved PN and CM uses both fall within rare ATTR amyloidosis indications and each has FDA orphan exclusivity. CMS final-guidance announcement, 2025-09-30; FDA orphan record, accessed 2026-08-22

INTERPRETATION — This is a material thesis-positive change relative to the June baseline. It does not extend patents or regulatory exclusivity, and it is not a permanent guarantee against negotiation. It does reduce the specific risk that a second orphan approval automatically strips the federal exclusion. A future non-orphan indication, further rulemaking, or legislation could change the result.

FACT — FDA issued an untitled letter dated April 23, 2026 over an AMVUTTRA consumer webpage that FDA considered false or misleading. FDA untitled letter, 2026-04-23 This followed an earlier 2025 promotional letter that FDA subsequently closed out. FDA pharmaceutical untitled-letter index, accessed 2026-08-22

INTERPRETATION — This is promotional-compliance hygiene, not evidence of a new product-safety or label problem. Repetition matters: another escalation would suggest deficient review controls and could constrain messaging during a critical launch. On current evidence it is a monitor, not a central industry thesis.

FACT — Alnylam relies on contract manufacturers and identifies Agilent as the sole active-ingredient manufacturer for AMVUTTRA, ONPATTRO, and GIVLAARI. It announced an expansion in Norton, Massachusetts, using siRELIS enzymatic ligation to add capacity and potentially reduce cost, but qualified CMO alternatives remain limited. Alnylam 2025 10-K, filed 2026-02-12

INTERPRETATION — Process know-how and capacity planning reinforce the supply moat, but single-source concentration is a fragility rather than an advantage. Internal capacity can improve bargaining power and continuity only after qualification and scale-up are demonstrated.

Clinical and commercial growth map

FACT — Core TTR. Q2 U.S. TTR revenue increased about $106M sequentially. Alnylam attributed roughly $129M to demand, offset by approximately $20M of inventory and modest net-price effects; international TTR revenue increased about $14M. Management expects modest sequential net-price declines and a mid-single-digit year-over-year decline. Alnylam Q2 release and call, 2026-07-30

INTERPRETATION — Volume remains strong, but revenue growth will increasingly need to overcome price mix and normal launch working-capital effects. First-line diagnosis and treatment growth is more repeatable than second-line switches, but it requires a larger, slower market-development effort.

FACT — Rare products. GIVLAARI and OXLUMO generated $89.8M and $52.1M in Q2, respectively; total rare-product revenue was $141.9M, approximately 11% year-over-year growth. Alnylam Q2 release, 2026-07-30

INTERPRETATION — These franchises provide durable, growing cash flow and commercial infrastructure but are too small to change current concentration. The P&L remains an AMVUTTRA/TTR story.

FACT — Pipeline. During or after Q2, Alnylam began Phase 2 work for ALN-6400 in von Willebrand disease/heavy menstrual bleeding and mivelsiran in Down syndrome-associated Alzheimer’s disease; fully enrolled the Phase 2 cAPPricorn-1 CAA study; advanced ALN-6222 into Phase 1 for obesity; and disclosed that partner Regeneron’s cemdisiran gMG application had FDA Priority Review with a November 2026 action date. Phase 1 ALN-HTT02 Huntington’s results were scheduled for October 23, 2026, after this cutoff. Alnylam Q2 2026 10-Q, filed 2026-07-30; Alnylam neuroscience update, 2026-07-15

INTERPRETATION — The pipeline is broad enough to support a platform claim, but today’s valuation-quality evidence should distinguish three levels: approved-product validation; partner/regulatory validation; and wholly owned clinical-outcomes validation. Only the first is mature. Mivelsiran biomarker lowering and tolerability support CNS delivery, but they do not yet demonstrate patient benefit. The Inceptive AI collaboration may improve discovery workflow; it is not itself evidence of a new moat. Alnylam–Inceptive announcement, 2026-06-03

Marathon capital-cycle view

INTERPRETATION — Stage. RNAi and ATTR are in a high-return attraction / expanding-supply phase. Orphan pricing, clinical validation, and Alnylam’s profitability have drawn capital from dedicated RNAi companies and large pharmaceutical firms. “Capacity” is not merely factories: it is target programs, trial sites, specialist salesforces, diagnostic programs, licensed delivery, and qualified oligonucleotide manufacturing. Because those investments have multi-year lags, today’s high margins induce the late-stage competition visible in 2030-era ATTR trials.

FACT — Near-term candidate supply contracted when eplontersen missed in CM, but medium-term modality supply remains broad: an entrenched Pfizer stabilizer, rapidly scaling Attruby, one-time CRISPR editing in Phase 3, two Phase 3 antibodies, Chinese gene-editing programs, and Alnylam’s own successor. Alnylam’s filing lists additional earlier candidates including Attralus AT-02 and China-origin editors ART-001 and YOLT-201. Alnylam Q2 2026 10-Q, filed 2026-07-30

INTERPRETATION — Returns implication. Wainua’s failure creates temporary scarcity value for approved therapies, but it does not reverse the capital cycle. Pfizer’s expected mid-2031 generic entry may compress the price umbrella just as late-stage new modalities mature. Sustained abnormal returns therefore require continued outcomes differentiation, evidence generation, and self-cannibalization through nucresiran—not merely category growth.

INTERPRETATION — Reinvestment quality. Q2’s 28% R&D growth and 8% SG&A growth are rational if TRITON, CNS delivery, hypertension, and hematology yield differentiated franchises. They are value-destructive if Alnylam simply adds duplicative late entrants to increasingly supplied targets. The highest-quality reinvestment is platform-extending clinical validation that competitors cannot cheaply replicate; the lowest-quality is commercially expensive target duplication without a meaningful efficacy, safety, dosing, or access advantage.

ASSUMPTION — ATTR diagnosis and treated prevalence continue to expand materially through the decade. Management estimates about 200,000 U.S. patients and 80% untreated, but those figures are company estimates rather than independently adjudicated prevalence and treatment data. Alnylam Q2 call transcript, 2026-07-30

OPEN QUESTION — Does incremental diagnosis remain economically attractive as screening moves from advanced specialist cohorts to lower-risk populations? The answer determines whether market growth strengthens Alnylam’s scale advantage or merely subsidizes competitors’ entry.

Prior bull/bear falsification scorecard

Bull case tests

1. Prior compound kill criterion: a quarter with sequential first-line CM share loss to Attruby and a TTR guide cut — YELLOW / PARTIALLY TRIGGERED.
   • FACT — The guidance-cut leg occurred. Alnylam Q2 release, 2026-07-30
   • OPEN QUESTION — There is no independently disclosed quarterly first-line share series proving AMVUTTRA lost share sequentially. Alnylam says share remains strong/gradually improving; BridgeBio says Attruby first-line share is rising. The compound test is not fully met, but one economically important leg is unequivocally broken.
2. Defend/grow first-line position above the prior threshold — UNVERIFIED / TRACKING.
   • FACT — Management reports strong utilization among existing prescribers and says first-line starts now drive about 80% of category growth. Alnylam Q2 call transcript, 2026-07-30
   • INTERPRETATION — Category mix is not AMVUTTRA share. Independent claims evidence is still required.
3. Deliver original $4.4–$4.7B FY26 TTR ramp — FALSIFIED.
   • FACT — New range is $4.2–$4.5B because second-line demand normalized. Alnylam Q2 release, 2026-07-30
4. Show operating leverage — CONFIRMED THIS QUARTER, with a gross-margin caveat.
   • FACT — GAAP operating income was $231M versus a loss a year ago, although product gross margin declined because AMVUTTRA’s Sanofi royalty burden rose with sales. Alnylam Q2 release, 2026-07-30
5. Positive beyond-TTR Phase 2/3 readout — NOT YET MET.
   • FACT — Programs advanced and mivelsiran has biomarker/safety observations, but no new decisive Phase 2/3 clinical-outcomes readout has validated a wholly owned non-TTR franchise since the baseline.

Bear case tests

1. Prior bear falsifier: two or more consecutive quarters of accelerating TTR growth with stable/rising first-line share plus a positive beyond-TTR Phase 2/3 readout — NOT FALSIFIED.
   • FACT — Q2 TTR demand was strong, but the guide was cut and the required beyond-TTR outcomes readout has not occurred. First-line share remains management-reported rather than independently verified.
2. Bear claim that Wainua would intensify near-term CM competition — MATERIALLY WEAKENED.
   • FACT — CARDIO-TTRansform missed its primary endpoint. Full data and regulatory strategy remain open. Ionis, 2026-07-09
3. Bear claim that multiple orphan indications create an imminent IRA exclusion problem — INVALIDATED UNDER CURRENT LAW.
   • FACT — The statutory exclusion is broader for IPAY 2028 implementation. CMS, 2025-09-30
4. Bear claim that ATTR is competitive and share is contestable — CONFIRMED.
   • FACT — Attruby grew about 23% sequentially in Q2 while Alnylam cut its TTR guide. This does not prove Attruby caused the entire cut, but it confirms a multi-product market rather than captive demand. BridgeBio Q2 release, 2026-08-10; Alnylam Q2 release, 2026-07-30

Synthesis and monitoring priorities

INTERPRETATION — Business quality remains high because Alnylam combines clinically validated delivery, recurring platform output, global commercialization, positive operating cash generation, and enough scale to finance its own successor products. The moat should not be described as broad customer captivity. Its strongest components are IP/know-how, accumulated human data, economies of scope, and TTR-specific commercial scale. Its weakest components are switching barriers for new patients and insulation from cross-modality competition.

INTERPRETATION — Industry structure is attractive but capital-cycle crowded. Near-term supply tightened after eplontersen’s failure and policy protection improved, while the longer horizon remains exposed to rapidly scaling stabilizers, tafamidis genericization, gene editing, antibodies, and Alnylam’s need to replace AMVUTTRA with nucresiran. The key question is not whether ATTR grows; it is whether Alnylam captures that growth at attractive incremental economics while defending differentiation.

OPEN QUESTIONS — next evidence required:

• Independent quarterly first-line AMVUTTRA and Attruby new-to-brand share, separated from total category growth and switches.
• Full CARDIO-TTRansform data, especially monotherapy, stabilizer-background, safety, and payer-relevant subgroup results.
• Whether plans restrict silencer-plus-stabilizer combinations more aggressively after CARDIO-TTRansform.
• Confirmation of tafamidis settlement dates and expected generic entry in Pfizer’s detailed settlement disclosure.
• TRITON-CM enrollment, endpoint hierarchy, and whether Alnylam modifies design after the eplontersen result.
• Decisive Phase 2/3 clinical-outcomes validation beyond TTR; biomarkers alone do not close the platform-translation question.
• Demonstrated qualification and economics of Norton/siRELIS capacity relative to the Agilent single-source exposure.

Primary sources consulted

• Alnylam Q2 2026 earnings release / SEC Exhibit 99.1, 2026-07-30
• Alnylam Q2 2026 Form 10-Q, filed 2026-07-30
• Alnylam 2025 Form 10-K, filed 2026-02-12
• FDA AMVUTTRA prescribing information, revised 2025-03
• FDA AMVUTTRA orphan-drug record, accessed 2026-08-22
• CMS Medicare negotiation IPAY 2028 announcement, 2025-09-30
• Ionis CARDIO-TTRansform update, 2026-07-09
• BridgeBio Q2 2026 results, 2026-08-10
• Regeneron Q1 2026 Form 10-Q, filed 2026-05
• ClinicalTrials.gov TRITON-CM NCT07052903, updated 2026-06-12
• FDA AMVUTTRA untitled letter, 2026-04-23

3. Financial Quality, Capital Allocation, Governance, and Insiders

Update conclusion

• FACT — The Q2 operating result was strong, but the commercial reset is thesis-negative. Q2 revenue was $1.291 billion (+67% year over year), operating income was $231 million versus a $16 million loss, and free cash flow was approximately $292 million. However, management reduced 2026 TTR product-revenue guidance from $4.4-$4.7 billion to $4.2-$4.5 billion and total product guidance from $4.9-$5.3 billion to $4.7-$5.1 billion. The rare-disease guide was unchanged, while collaboration/royalty guidance increased. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22; Q2 earnings release, filed 2026-07-30, accessed 2026-08-22)
• INTERPRETATION — This is a yellow, not red, falsification signal. Management attributes the reduction to faster normalization of second-line pent-up demand after launch, not erosion of first-line demand. The numerical guide cut satisfies one half of the prior bull-case falsification test, but the concurrent claim that approximately 80% of new patients are first-line does not establish sequential first-line share loss. The test therefore moves from green to amber; it has not fully triggered. (Q2 transcript, 2026-07-30, accessed 2026-08-22)
• FACT — Profit and cash-flow quality improved, although the accounting is not economically simple. H1 operating cash flow was $397 million and filing-defined free cash flow was $341 million, slightly below H1 net income of $370 million after a meaningful working-capital cash use. H1 also included $157 million of stock compensation and $145 million of non-cash interest accretion on development/royalty funding liabilities. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)
• FACT — The balance sheet is liquid but not simply “net cash.” Cash and marketable debt securities were $3.308 billion, against $1.011 billion of convertible-debt carrying value and $1.720 billion of current and long-term development/royalty funding liabilities. A conservative economic net-cash calculation is therefore only about $577 million before lease liabilities. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)
• FACT — No new insider signal has appeared since the prior research date. The most recent Forms 4 remain the two filed June 3, 2026. The Q2 Item 5© disclosure says no director or officer adopted or terminated a Rule 10b5-1 or non-Rule arrangement during the quarter. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22; latest Pyott Form 4, filed 2026-06-03, accessed 2026-08-22)

Financial record

Multi-year progression

All figures are GAAP and in $ millions except margins. FCF is operating cash flow less purchases of property, plant, and equipment.

FACT — Source and reconciliation. The annual figures reconcile to Alnylam’s five-year SEC corpus; H1 2026 reconciles to the latest 10-Q. The progression shows the 2025 profitability inflection was not a single-quarter artifact: H1 2026 operating income already approximately equaled all of FY2025. (SEC 10-K filings list, accessed 2026-08-22; 2025 10-K, filed 2026-02-12, accessed 2026-08-22; Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)

Latest-quarter detail

FACT — Operating leverage remains real. Q2 operating margin was 17.9%, and the year-over-year incremental operating margin was approximately 47.9%. Sequentially, though, operating margin declined from about 23.0% in Q1 even as revenue grew 10.6%, because product gross margin stepped down and late-stage R&D increased. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)

Revenue composition and quality

FACT — Product mix is now the dominant quality-of-earnings driver. Product revenue represented 90.8% of Q2 revenue; collaboration revenue was only 3.7% and royalties 5.6%. This is higher quality than milestone-heavy 2023-2025 revenue, but product concentration is high. Q2 AMVUTTRA revenue was $1.012 billion, ONPATTRO $18 million, total TTR $1.030 billion, GIVLAARI $90 million, and OXLUMO $52 million. TTR represented 87.9% of product revenue. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)

FACT — Collaboration revenue remains lumpy. Q2 collaboration revenue comprised $41.9 million from Roche, $5.0 million from Regeneron, and $0.3 million from other arrangements. The initial Regeneron research-exclusivity period expired in May 2026; nominated programs continue, but Alnylam is no longer required to work exclusively with Regeneron on new eye and CNS discovery. In June, Alnylam entered an AI/RNAi discovery collaboration with Inceptive and invested $15 million in its preferred stock. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)

INTERPRETATION — Product growth is more repeatable than milestones, but TTR concentration raises the cost of a launch-model miss. The reduced TTR range is therefore more decision-relevant than the offsetting increase in collaboration and royalty guidance. Royalty growth, primarily from Leqvio, is economically positive but must be analyzed together with the associated funding-liability accretion rather than as costless high-margin revenue.

Margins and quality of earnings

FACT — Q2 product gross margin was approximately 74.6%, versus 78.9% a year earlier and about 80.0% in Q1. The principal structural reason is the AMVUTTRA blended royalty payable to Sanofi, which rises with annual global sales: 15% through $150 million, 17.5% from $150-$300 million, 20% from $300-$500 million, 25% from $500 million-$1.5 billion, and 30% above $1.5 billion. Faster AMVUTTRA growth therefore mechanically lowers reported product gross margin. The approximately 76.9% consolidated gross margin sometimes shown by data vendors includes collaboration and royalty revenue and should not be confused with filing-derived product gross margin. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)

FACT — Cash conversion was positive but contained material non-cash components. H1 OCF of $397.2 million exceeded net income by $26.7 million. Add-backs included $156.8 million of SBC and $145.3 million of non-cash interest expense, while receivables, prepaid/other assets, and payables/accruals together consumed approximately $322 million. Standalone Q2 OCF was about $326.7 million and FCF about $292.0 million. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22; Q1 2026 10-Q, filed 2026-04-30, accessed 2026-08-22)

INTERPRETATION — The earnings improvement is operationally credible, but GAAP net income overstates the cash economics of the financing structure. The royalty/development liability accretion is non-cash today, yet represents the compounding economic cost of prior monetizations and future payment obligations. Conversely, working-capital investment is consistent with rapid commercial growth and is not automatically a deterioration in underlying demand.

R&D economics and return on capital

FACT — R&D intensity continues to fall while absolute investment rises. R&D was approximately 94% of revenue in 2021, 85% in 2022, 55% in 2023, 50% in 2024, 36% in 2025, and 31.7% in H1 2026. Q2 R&D rose 28% to $413 million; clinical trial and outside-services expense rose 74% to $244 million, driven principally by ZENITH and the TRITON cardiomyopathy and polyneuropathy studies. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22; 2025 10-K, filed 2026-02-12, accessed 2026-08-22)

INTERPRETATION — This is the desired capital-cycle pattern: falling R&D intensity because the commercial base is scaling, not because the company is starving the platform. The counter-risk is program proliferation: a broad clinical portfolio can absorb the new cash generation faster than it creates risk-adjusted value, particularly where incentives reward pipeline breadth and revenue but not return on incremental research capital.

FACT — Reported ROIC is not a reliable stand-alone measure for Alnylam. A third-party calculation gives FY2025 ROIC of 28.4% and return on capital of 32.6%; the filing supports the $501.6 million operating-profit numerator but not the economic usefulness of the denominator. Decades of R&D were expensed, year-end accumulated deficit was about $6.7 billion, and balance-sheet financing includes funding liabilities rather than conventional debt alone. ROIC was not meaningful in the loss years 2020-2024 and no defensible filing-based quarterly ROIC is available for Q2. (2025 10-K, filed 2026-02-12, accessed 2026-08-22; ROIC.ai annual financials, accessed 2026-08-22)

ASSUMPTION — A rough research-capital sanity check is more conservative. Applying an illustrative 2.9% cash tax rate to FY2025 operating income produces about $487 million of NOPAT; dividing by the roughly $6.7 billion accumulated deficit gives approximately 7.3%. This is not accounting ROIC and the accumulated deficit is not a precise R&D asset, but it better communicates that platform-level returns have only recently become positive.

SBC and dilution

FACT — SBC burden is moderating as a percentage of revenue, but dilution persists. Q2 SBC was $86.6 million, down 22% year over year; H1 SBC was $156.8 million, or 6.4% of revenue versus 12.3% in H1 2025. Full-year SBC rose from $139.9 million in 2020 to $348.2 million in 2025. The updated 2026 non-GAAP guide implies SBC of $330-$380 million. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22; Q2 earnings release, filed 2026-07-30, accessed 2026-08-22)

FACT — Common shares outstanding were 133.734 million at June 30, 2026, versus 132.376 million at year-end 2025 and 130.977 million a year earlier. That is 1.0% dilution in six months and 2.1% year over year. Q2 diluted weighted-average shares of 138.281 million were 3.5% above basic weighted-average shares. Shares outstanding have grown from 116.427 million at year-end 2020, about a 2.8% annualized rate through Q2 2026. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)

INTERPRETATION — SBC is no longer preventing positive owner earnings, but it remains an economic expense. The combination of roughly mid-single-digit SBC/revenue and low-single-digit annual dilution is improving, not immaterial.

Liquidity, debt, convertibles, and funding liabilities

FACT — Convertible maturities are manageable, but potential dilution should be monitored. The company had $661.3 million principal of 0% 2028 notes, carrying value $649.8 million and conversion price $670.11, plus $362.8 million principal of 1% 2027 notes, carrying value $361.2 million and conversion price $286.20. The 2027 notes were not convertible during Q3 2026. The 2028 issuance principally refinanced $637.8 million of 2027 notes and funded $35.3 million of capped calls. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)

FACT — Funding liabilities are the more important economic encumbrance. The Leqvio royalty liability carried at $1.517 billion and had estimated fair value of $1.960 billion. Its effective interest rate rose from 10% to 14% because stronger expected Leqvio royalties increase the payments due to Blackstone. Vutrisiran and zilebesiran funding liabilities carried at $181 million and $22 million but had disclosed fair values of $555 million and $120 million, respectively, reflecting contingent future payments. H1 interest expense was $151 million versus $55 million of interest income. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)

FACT — Revolver capacity is intact. There were no borrowings under the $500 million revolver due September 2030, with $17.5 million of letters of credit outstanding. Covenants include maximum leverage of 3.75x and minimum interest coverage of 3.0x. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)

Capital allocation assessment

FACT — Allocation since the prior report remains organic reinvestment, not acquisition-led expansion. There is no material acquisition or goodwill build, no dividend, and no repurchase program. The incremental allocation is toward three Phase 3 programs and a $15 million Inceptive preferred-stock investment tied to a discovery collaboration. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)

INTERPRETATION — Reinvestment is strategically coherent but needs a higher hurdle rate now that the core franchise is cash-generative. RNAi know-how, IP, commercial infrastructure, and clinical execution are genuine barriers; late-stage spend on label expansion can exploit these assets. The Q2 guide cut nevertheless shows that commercial forecasting and research breadth must be assessed separately from raw program count.

INTERPRETATION — Prior royalty monetizations were valuable liquidity bridges but expensive capital. The Leqvio liability’s 14% effective interest rate and $1.96 billion fair value against the original $1 billion received in 2020 demonstrate the opportunity cost. Management should not receive full economic credit for growing royalty revenue without also recognizing the financing claim that growth creates.

Compensation and governance

FACT — CEO Yvonne Greenstreet’s 2025 compensation was $14.868 million: $1.404 million salary, $5.513 million stock awards, $4.363 million options, $3.563 million non-equity incentive compensation, and other compensation. The CEO’s package was 93% variable; regular long-term grants are generally 50% PSUs, 25% RSUs, and 25% options. (2026 proxy, filed 2026-04-06, accessed 2026-08-22)

FACT — Annual incentive payout reached the 200% maximum. The product-revenue maximum was $2.5 billion versus $2.987 billion actual; non-GAAP operating-income maximum was $550 million versus $850 million actual. By contrast, non-GAAP R&D plus SG&A actual of $2.182 billion missed the $2.137 billion target. Metrics reward culture, pipeline/development milestones, products/financial performance, operating income, and relative share performance; there is no explicit ROIC, FCF, or per-share owner-earnings measure. (2026 proxy, filed 2026-04-06, accessed 2026-08-22)

FACT — The March 2026 special CEO PSU award is unusually price-focused. Target vesting ranges from 50% at a $500 stock-price hurdle to 200% at $800, based on the highest 30-day average during the final six months before December 31, 2029; nothing vests below $500. This corrects the prior baseline’s incomplete description, which omitted the $500 threshold. (2026 proxy, filed 2026-04-06, accessed 2026-08-22)

FACT — Governance protections include ownership guidelines, a clawback, and prohibitions on hedging and pledging; change-in-control treatment does not use single-trigger acceleration. Say-on-pay received 111.8 million votes for and 8.6 million against, or approximately 92.9% support excluding abstentions, down modestly from roughly 94% in 2025. Benjamin Cravatt joined the board effective June 1 and received an initial option grant valued at $600,000. (2026 proxy, filed 2026-04-06, accessed 2026-08-22; annual-meeting 8-K, filed 2026-05-27, accessed 2026-08-22; Cravatt Form 4, filed 2026-06-03, accessed 2026-08-22)

INTERPRETATION — Incentives are strongly aligned with growth and shareholder price outcomes, less clearly with capital efficiency. The absent per-share return-on-reinvestment measure matters more as the business transitions from funding scarcity to cash generation.

Insider and 10b5-1 sweep

FACT — Corpus coverage. The refreshed trailing-60-month SEC census from 2021-08-22 contained 411 filings, including 219 Forms 4, 57 8-Ks, 15 10-Qs, five 10-Ks, and five DEF 14As. The repository fetch mirrored 326 source documents and passed its integrity check on 2026-08-22.

FACT — No post-baseline transaction exists. The latest filings are June 3: director David Pyott exercised 3,830 options and sold the same number of shares for approximately $1.146 million under a Rule 10b5-1 plan; new director Benjamin Cravatt received 4,393 options at a $295.63 exercise price. There were no later Forms 4 through 2026-08-22. (Pyott Form 4, filed 2026-06-03, accessed 2026-08-22; Cravatt Form 4, filed 2026-06-03, accessed 2026-08-22)

FACT — The 24-month machine-readable sweep found 101 filings and 811 transaction rows. Rows included 629 sale lines, 103 awards, 74 option exercises, two purchases, two gifts, and one tax-withholding transaction. The sale-row count overstates discrete decisions because a single order is reported across many price lines. Aggregated, there were 83 owner/date sale events representing about 401,000 shares and $140.7 million; 46 events were flagged as 10b5-1 and 37 were not. The only code-P purchases were director Colleen Reitan’s 36 shares for $10,363 in August and October 2024, reported later in one May 2025 filing; the same 36 shares were sold in April 2025. (Reitan Form 4, filed 2025-05-12, accessed 2026-08-22)

INTERPRETATION — Insider activity remains neutral-to-cautious, not a fresh thesis change. There is meaningful selling and little open-market buying, but much is plan-driven, linked to option exercise/vesting, or tax-related. The absence of a post-June-21 Form 4 means the insider evidence has not worsened since the baseline.

FACT — Item 5© is clean for Q2. No director or officer adopted or terminated a Rule 10b5-1 plan or non-Rule trading arrangement during the quarter. This does not mean no one had a plan; several Forms 4 explicitly identify sales under previously adopted plans. (Q2 2026 10-Q, filed 2026-07-30, accessed 2026-08-22)

Material changes since 2026-06-21 and risk inputs

1. FACT — Commercial expectations reset lower: TTR and total product guidance were cut by $0.2 billion at both ends. This is the central negative delta.
2. FACT — Reported execution stayed strong: Q2 TTR revenue was $1.030 billion and Q2 FCF was approximately $292 million. H1 operating margin reached 20.3%.
3. FACT — Mix costs became more visible: AMVUTTRA’s Sanofi royalty tiers compressed product gross margin as sales scaled, and net price is expected to decline at a mid-single-digit rate year over year, according to management. (Q2 transcript, 2026-07-30, accessed 2026-08-22)
4. FACT — The collaboration portfolio evolved: Regeneron’s new-program exclusivity expired and Inceptive was added; the strategic effect is more freedom for new eye/CNS work, with modest new capital at risk.
5. FACT — No new SEC governance or insider deterioration appeared: Q2 Item 5© was negative and the Form 4 trail ends before the prior research date.

Prior falsification-test scorecard

OPEN QUESTION — First-line share cannot be independently reconciled from SEC filings. The next two quarters should be judged on patient starts, first-line mix, prescriber breadth, inventory effects, price/mix, and whether the revised TTR range can be met without a second guidance cut.

OPEN QUESTION — Funding-liability cash economics need continued tracking. Future Leqvio, vutrisiran, and zilebesiran cash payments should be modeled alongside royalties and product economics; the large gap between carrying and fair values is a useful risk input.

OPEN QUESTION — Capital-allocation discipline is now more important than liquidity. Track the number of clinical programs, late-stage spending by program, terminations, probability-adjusted milestone economics, and whether compensation adds an explicit per-share return or cash-return measure.

Source-corpus note

The SEC corpus was refreshed on 2026-08-22 with repository scripts using a 2021-08-22 start date. The filing census is saved at output/ALNY/2026-08-22/_scratch/sec_census_2021-08-22.txt; source integrity passed. The latest reviewed primary documents were the 2025 10-K, Q1 and Q2 2026 10-Qs, the Q2 earnings 8-K and exhibit, the 2026 DEF 14A, the annual-meeting 8-K, all trailing-60-month Forms 4, and Q2 Item 5©.

4. Market Positioning, Events, Risks, and Embedded Expectations

1. What changed since the baseline

The most important change is not simply a lower share price. The evidence now shows a real commercial-expectations reset:

• On July 30, Alnylam cut 2026 TTR revenue guidance from $4.4-$4.7B to $4.2-$4.5B and total product revenue guidance from $4.9-$5.3B to $4.7-$5.1B. The company attributed the miss to a larger-than-understood early bolus of pent-up second-line demand that normalized. The shares fell 28.31% that day, the largest one-day decline in the trailing five years. Alnylam Q2 release / SEC Exhibit 99.1, 2026-07-30; AZI price history, accessed 2026-08-22.
• The cut occurred despite strong reported Q2 results: total revenue was $1.291B, AMVUTTRA revenue $1.012B, total TTR revenue $1.030B (+89% YoY, +13% sequentially), and GAAP operating income $231M. This is an expectations/demand-shape break, not evidence that current revenue contracted. Q2 release.
• The baseline’s compound bull kill criterion is partially triggered: the specified guidance cut occurred, but no independent data establish sequential first-line AMVUTTRA share loss. Management disclosed that about 80% of category treatment initiations were first-line, but that is category mix, not Alnylam’s first-line share. It did not provide a numeric current share series. [ROIC transcript for ALNY Q2 2026, dated 2026-07-30, accessed 2026-08-22; guidance checked to SEC exhibit.]
• The July 9 failure of Ionis/AstraZeneca’s CARDIO-TTRansform eplontersen trial removed or delayed a branded silencer competitor in CM, but ALNY’s initial +17.0% opening gap reversed to a -3.3% close. The market did not retain the apparent competitive-relief bid; a reasonable, labeled inference is that investors also saw combination-therapy, contemporary-standard-of-care, or RNA-silencing class-readthrough uncertainty. Ionis primary release, 2026-07-09; AstraZeneca 6-K exhibit; AZI price history.
• A risk omitted from the June memo must be restored: an October 2025 U.S. Attorney’s Office for the District of Massachusetts subpoena concerning government price reporting and distributor fee/discount arrangements remains active. Alnylam says it produced responsive records and continues to engage; it had no material loss contingency accrued at June 30. Alnylam Q2 10-Q, Notes 11 and risk factors.

2. Five-year event and price map

Price reactions are close-to-close unless otherwise noted. Event attribution is to primary sources; rows without a discrete filing are explicitly labeled market interpretation.

3. Current tape, trend, and relative performance

The latest available close is $236.22 on Friday, August 21. ALNY is below its 21-, 50-, and 200-day exponential moving averages of $238.22, $259.64, and $310.06, respectively, with 21 < 50 < 200. It is 51.9% below its October 2025 closing high, 15.0% above the July 30 crash close, and still 96.2% above its May 2022 five-year low. [AZI daily data, accessed 2026-08-22.]

Inference: this is not a sector risk-off episode. The biotechnology indices and most mature-biotech/rare-disease controls appreciated strongly while ALNY fell. IONS is the short-horizon exception because it owned the failed competitor asset, yet its one-year return remained positive. The cross-sectional evidence therefore supports company-specific commercialization and expectations risk as the dominant driver.

4. FactorsToday positioning and risk-adjusted record

Exposure snapshot

The required All Factors ElasticNet model is dated 2026-07-31 and uses a 756-day window. It reports R-squared 0.220, adjusted R-squared 0.196, and 22 active factors. Principal active loadings are:

Value, Quality, Growth, and Low Volatility are absent from the active set. Under the ElasticNet specification, absence means the coefficient was shrunk to zero; it is not missing data. FactorsToday’s specific-volatility endpoint estimates 42.9% annualized stock-specific volatility. With only about 22% of variance explained, ALNY is fundamentally an idiosyncratic security despite its strong biotech beta.

Risk-adjusted history

FactorsToday annualizes the sub-one-year returns, so they should not be read as raw holding-period moves.

The five-year Sharpe is now effectively zero. Long-run return potential has historically come with venture-like volatility and very deep drawdowns; the latest reset is material but not unprecedented for the security.

Regime

The biotechnology factor returned +6.1% over 21 days (z +2.10), +11.3% over 63 days (z +2.33), and +11.6% over 252 days (z +1.23). Health Care returned +7.1% over 63 days (z +1.45). Momentum, by contrast, was -3.1% over 21 days (z -1.22), while Value was +5.3% over 63 days (z +1.03) and +12.6% over 252 days (z +1.50). [FactorsToday historic factor returns, pulled 2026-08-22.]

Positioning conclusion: ALNY is not a factor-supported one-way-street long. It has weak negative Momentum loading, no active Quality or Value loading, and exceptionally high residual risk. The favorable biotech regime makes the relative failure more informative, not less: the current setup is a company-specific falling knife rather than a broad-beta washout.

FactorsToday’s similarity controls also support the chosen comparison set: IBB (0.917), REGN (0.909), FBT (0.902), and GMAB (0.891) rank highly. Similarity is a return-factor control, not a fundamental valuation comp rule.

5. Recent news and transcript triage

ROIC transcript-control note: the general earnings-call list endpoint returned unrelated companies when filtered for ALNY, consistent with the known identifier bug. The direct NASDAQ:ALNY, Q2 2026 transcript resolved to 2026-07-30 and was used only after date, company, quarter, and body validation. ROIC company-news results were used for discovery; material attribution above was checked against SEC/company/competitor primary sources.

6. Risk and variant-perception inputs

What consensus has newly learned

• The 2026 launch curve was front-loaded by more pent-up second-line demand than management understood.
• A branded silencer competitor failed, but the result is not clean evidence that all TTR silencing on top of stabilizers works; the full dataset and TRITON-CM design response matter.
• Strong headline growth can coexist with a cut when the prior embedded ramp was more aggressive than reported numbers made obvious.

Bull-side variant inputs

• The guide cut is approximately 4% at midpoint for TTR, while Q2 TTR revenue still grew 89% YoY and 13% sequentially. If revised guidance proves conservative and first-line share rises, the market may have extrapolated a forecasting error into a franchise impairment.
• CARDIO-TTRansform reduces a near-term same-modality CM supply threat. In Marathon terms, candidate supply tightened even as the broader ATTR capital cycle remains crowded.
• At $236.22, the standard live EV is much lower than the June memo’s period-end/vendor EV; the multiple now embeds a materially less flawless launch.

Bear-side variant inputs

• The best early launch cohorts may have been exhausted, making revised growth dependent on harder first-line conversion against tafamidis/Attruby rather than second-line switches.
• Without an independent numerical first-line share series, management’s gradual-progression language cannot falsify share loss. BridgeBio’s continued Attruby growth makes this the most important missing datapoint.
• CARDIO-TTRansform may make payers more skeptical of combination therapy and may expose modern-background-therapy endpoint difficulty for nucresiran. Alnylam’s willingness to revisit TRITON-CM analytical choices confirms that the readthrough is not trivial.
• Sanofi’s AMVUTTRA royalty tier and mid-single-digit net-price decline pressure incremental product economics even when revenue grows.
• The USAO subpoena, 340B reimbursement proposal, and UT patent case add asymmetric legal/reimbursement tails not visible in a simple revenue multiple.

Explicit update tests

• Prior bull kill criterion: partially triggered, not fully met. The guide cut occurred; independently verified sequential first-line share loss has not.
• Prior bear falsifier: not met. There are not two consecutive quarters of accelerating TTR growth plus independently stable/rising first-line share plus a decisive beyond-TTR outcomes readout.
• Evidence that would change the interpretation next: independently sourced monthly/quarterly AMVUTTRA vs Attruby/tafamidis first-line new-to-brand share; Q3 and Q4 growth versus the revised guide; full CARDIO-TTRansform subgroup/event data; any TRITON-CM protocol/analysis change; and a decisive non-TTR Phase 2/3 readout.

7. Valuation and embedded expectations

ROIC’s latest Q2 enterprise-value record is a period-end figure using a $301.03 share price; it must not be treated as current. Recomputed at the August 21 close using 133.734M June 30 shares:

Alnylam also carries $1.720B of current and long-term future royalty/development-funding liabilities. Standard ROIC EV excludes them. Treating them as debt-like produces an economic EV of about $31.27B, or 6.51x TTM revenue and 5.69x midpoint 2026 total revenue. Both conventions are shown so this financing obligation is not buried.

Owner-FCF check

H1 2026 operating cash flow was $397.2M and capital expenditure was $56.5M, producing conventional FCF of $340.7M. Because the cash-flow statement adds stock compensation back, subtracting H1 SBC of $156.8M gives $183.9M of owner FCF after SBC. This is the correct place to charge SBC; subtracting it again from GAAP net income would double count it. A purely mechanical doubling of H1 owner FCF is about $368M, only 1.16% of current basic equity value. That is not a forecast—working capital and launch spending can be seasonal—but it shows that the current valuation still requires substantial future cash-conversion growth despite the headline earnings inflection. [Q2 10-Q cash-flow statement and expense footnote.]

2030 EV scenario frame

These are deliberately wide embedded-expectations scenarios, not forecasts, recommendations, or price targets. Future enterprise value is 2030 revenue x EBITDA margin x EV/EBITDA. The present-equivalent column discounts year-end 2030 EV back 4.36 years at 11%; it does not adjust for interim cash generation, future net cash/debt, taxes, dilution, or the runoff of royalty-funding liabilities.

For reference, current standard EV is $29.55B and current economic EV including funding liabilities is $31.27B. The grid therefore makes the central debate explicit: current valuation is above the discounted bear outcome but below the discounted base outcome. Most of the gap is explained by assumptions about durable CM share, successful internal franchise renewal, and whether R&D creates at least one material non-TTR profit pool. Multiple choice matters, but operating delivery matters more.

Relevant fundamental comparators:

• VRTX and REGN: profitable large-cap biotech durability/control multiples.
• UTHR: rare-disease, specialist-prescriber economics and high-margin commercial model.
• IONS: closest RNA-therapeutics platform/modality comparator, though economics and asset ownership differ.
• BBIO: direct ATTR-CM commercial competitor and best market-share pressure indicator.
• GMAB: profitable antibody-platform control; less direct commercially.
• IBB and FBT: regime/relative-return controls only, not fundamental-multiple comps.

AZI valuation_index control

The June report cited an ALNY composite own-history percentile near 24.6 and a P/S percentile near 0.02, then called the stock’s sales multiple the cheapest in public history. A fresh ALNY plus peer-control pull was attempted for ALNY, REGN, GMAB, BBIO, IONS, VRTX, and UTHR, but this session does not expose the required AZI_API_TOKEN; the endpoint returned no usable payload. Under the repository’s peer-control rule, the old percentile cannot be repeated as decision-useful evidence until a fresh cross-sectional control establishes that the feed was not recalibrated. The absolute live multiples above are usable because they were reconstructed from current price and filing figures; the own-history percentile claim is unverified and withheld.

8. Source ledger

• Alnylam Q2 2026 Form 10-Q, filed 2026-07-30: https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm
• Alnylam Q2 2026 earnings release, SEC Exhibit 99.1, 2026-07-30: https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/alny2026q2earningsrelease.htm
• Ionis CARDIO-TTRansform primary release, 2026-07-09: https://ir.ionis.com/news-releases/news-release-details/update-cardio-ttransform-phase-3-trial-eplontersen-adults
• AstraZeneca CARDIO-TTRansform 6-K exhibit, 2026-07-09: https://www.sec.gov/Archives/edgar/data/901832/000165495426006554/a6054l.htm
• Alnylam HELIOS-B primary release, 2024-06-24: https://investors.alnylam.com/press-release?id=28231
• Alnylam APOLLO-B primary release, 2022-08-03: https://investors.alnylam.com/press-release?id=26851
• FDA AMVUTTRA approval/orphan record: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=637618
• ROIC.ai: ALNY Q2 2026 transcript and TTM financial/EV fields, accessed 2026-08-22; transcript figures checked to SEC filing.
• AZI: ALNY/peer daily price histories, accessed 2026-08-22.
• FactorsToday: All Factors loadings, stock info, specific volatility, leaderboard, related stocks, and historic factor returns, pulled 2026-08-22.

Appendix A — Standard Diligence Questionnaire

Appendix B — Source Appendix and Evidence Hierarchy

Primary evidence consists of the 2025 Form 10-K; Q1 and Q2 2026 Forms 10-Q; the July 30 earnings 8-K and exhibit; the 2026 proxy and annual-meeting 8-K; the refreshed five-year Form 4 corpus; FDA labels, approvals and orphan records; CMS guidance; ClinicalTrials.gov; and dated Alnylam, Ionis, AstraZeneca, BridgeBio and Regeneron disclosures linked in the relevant sections. Q2 transcript statements are identified as management hypotheses unless reconciled to filed figures.

AZI daily histories support prices and returns; FactorsToday supports factor exposures, regime and risk statistics; ROIC.ai supports transcript retrieval and TTM cross-checks only after identity/date validation. A fresh AZI historical valuation percentile was unavailable because the session lacked the required token. The old “cheapest-ever” percentile is therefore excluded from decision-useful evidence. All scenario values are derived assumptions, not company guidance or forecasts.

Research Disclosure

This document is independent research prepared from public filings, company and competitor disclosures, regulator materials, market-data services, and explicitly labeled interpretations. It is not investment advice, an offer, or a solicitation. Clinical, regulatory, reimbursement, litigation, and market outcomes can differ materially from the scenarios discussed. Market prices and factor statistics are through 2026-08-21 unless otherwise stated.